Guardant Health, Inc. and NRG Oncology jointly initiate the NRG-GI005 study
Home » Guardant Health, Inc. and NRG Oncology jointly initiate the NRG-GI005 study

GH AMEA on Social MediaGuardant Health, Inc. and NRG Oncology jointly initiate the NRG-GI005 study
Guardant Health, Inc. and NRG Oncology jointly initiate the NRG-GI005 study
Guardant Health, Inc. and NRG Oncology jointly initiate the NRG-GI005 study
LinkedIn

Guardant Health, Inc. and NRG Oncology, a National Cancer Institute (NCI) funded National Clinical Trials Network group conducting clinical and translational research, have initiated the NRG-GI005 study to validate the clinical utility of Guardant Health’s molecular residual disease (MRD) assay as a diagnostic biomarker for selecting which patients with stage II colon cancer need adjuvant chemotherapy.

Open chat
Message us